Search Result

Results for "

senescence

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Antibiotic (1) Apoptosis (11) ATM/ATR (1) Autophagy (3) CDK (3) CMV (2) DNA/RNA Synthesis (3) E1/E2/E3 Enzyme (2) Endogenous Metabolite (1) ERK (2) FAK (1) Ferroptosis (2) FGFR (1) G-quadruplex (1) Glucosidase (1) Glutathione Peroxidase (1) Histone Methyltransferase (2) JNK (1) Keap1-Nrf2 (1) MDM-2/p53 (3) NF-κB (1) p38 MAPK (2) PAI-1 (2) PPAR (3) Reactive Oxygen Species (3) Sirtuin (4) Survivin (1) Telomerase (1) TRP Channel (2) Tyrosinase (1) VEGFR (1)
By Research Areas:	Cancer (25) Endocrinology (1) Infection (2) Inflammation/Immunology (6) Metabolic Disease (3) Neurological Disease (3)

By Targets:

Antibiotic (1)

Apoptosis (11)

ATM/ATR (1)

Autophagy (3)

CDK (3)

CMV (2)

DNA/RNA Synthesis (3)

E1/E2/E3 Enzyme (2)

Endogenous Metabolite (1)

ERK (2)

FAK (1)

Ferroptosis (2)

FGFR (1)

G-quadruplex (1)

Glucosidase (1)

Glutathione Peroxidase (1)

Histone Methyltransferase (2)

JNK (1)

Keap1-Nrf2 (1)

MDM-2/p53 (3)

NF-κB (1)

p38 MAPK (2)

PAI-1 (2)

PPAR (3)

Reactive Oxygen Species (3)

Sirtuin (4)

Survivin (1)

Telomerase (1)

TRP Channel (2)

Tyrosinase (1)

VEGFR (1)

By Research Areas:

Cancer (25)

Endocrinology (1)

Infection (2)

Inflammation/Immunology (6)

Metabolic Disease (3)

Neurological Disease (3)

Inhibitors & Agonists

Screening Libraries

Peptides

Natural
Products

Recombinant Proteins

Antibodies

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-153596

SNX7

Others Cancer

SNX7 is a Cyclin-Dependent Kinase Inhibitor (CDKI) pathway inhibitor. SNX7 can be used for research of senescence-related and other CDKI-related diseases .

SNX7	Others	Cancer
SNX7 is a Cyclin-Dependent Kinase Inhibitor (CDKI) pathway inhibitor. SNX7 can be used for research of senescence-related and other CDKI-related diseases .

HY-138936

SSK1 1 Publications Verification	p38 MAPK Apoptosis	Inflammation/Immunology
SSK1, a senescence-specific killing compound, is a β-galactosidase-targeted proagent attenuates inflammation. SSK1 is activated by lysosomal β-galactosidase and selectively killed senescent cells through the activation of p38 MAPK and induction of apoptosis .

HY-147359

Boanmycin

Antibiotic Apoptosis Cancer

Boanmycin is an antibiotic with antitumor activity that induces cellular senescence and apoptosis .

Boanmycin	Antibiotic Apoptosis	Cancer
Boanmycin is an antibiotic with antitumor activity that induces cellular senescence and apoptosis .

HY-N3642

Cristacarpin Erythrabyssin I; Erythrabissin I	Others	Cancer
Cristacarpin can be extracted from the stem bark of Erythrina suberosa, promotes endoplasmic reticulum (ER) stress, leading to sublethal reactive oxygen species (ROS) production and ultimately cell death through senescence .

HY-156334

FAK-IN-12	FAK	Cancer
FAK-IN-12 (Compound 12S) is a FAK inhibitor (IC₅₀ = 47 nM). FAK-IN-12 inhibits MGC-803, HCT-116 and KYSE30 cell proliferation (IC₅₀: 0.24, 0.45, 0.44 μM). FAK-IN-12 induces apoptosis and cellular senescence .

HY-118032

Bozepinib	Apoptosis Autophagy JNK ERK	Cancer
Bozepinib is a PKR (RNA-dependent protein kinase) activator and potently inhibits the HER-2 signaling pathway as well as JNK and ERK kinases. Bozepinib induces PKR-mediated apoptosis and synergizes with IFNα to trigger apoptosis, autophagy and senescence. Bozepinib also demonstrates in vivo antitumor and antimetastatic efficacy in xenografted nude mice .

HY-N12233

Condurango glycoside A	Apoptosis MDM-2/p53 Reactive Oxygen Species	Cancer
Condurango glycoside A is an activator of p53. Condurango glycoside A initiates ROS generation and up-regulates p53 expression. Condurango glycoside A induces apoptosis and pre-mature senescence associated with DNA damage in HeLa cells .

HY-17386

Rosiglitazone Maximum Cited Publications 84 Publications Verification BRL 49653	PPAR TRP Channel Autophagy Ferroptosis Apoptosis	Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Rosiglitazone (BRL 49653) is an orally active selective PPARγ agonist (EC₅₀: 60 nM, K_d: 40 nM). Rosiglitazone is an TRPC5 activator (EC₅₀: 30 μM) and TRPM3 inhibitor. Rosiglitazone can be used in the research of obesity and diabetes, senescence, ovarian cancer .

HY-17386B

Rosiglitazone potassium BRL 49653 potassium	PPAR TRP Channel Autophagy Apoptosis Ferroptosis	Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Rosiglitazone (BRL 49653) potassium is an orally active selective PPARγ agonist (EC₅₀: 60 nM, K_d: 40 nM). Rosiglitazone potassium is a TRPC5 activator (EC₅₀: 30 μM) and TRPM3 inhibitor. Rosiglitazone potassium can be used in the research of obesity and diabetes, senescence, ovarian cancer .

HY-161088

Anti-aging agent 1	Others	Others
Anti-aging agent 1 (compound 24) is a derivative of piperlongumine (HY-N2329) (PL). Anti-aging agent 1 exhibits a 50-fold enhancement in senolytic activity against senescent WI-38 fibroblasts compared to PL .

HY-N8211

Gypenoside L 2 Publications Verification	p38 MAPK ERK NF-κB	Inflammation/Immunology Cancer
Gypenoside L is a saponin that can be found in Gynostemma pentaphyllum. Gypenoside L increases the SA-β-galactosidase activity, promotes the production of senescence-associated secretory cytokines. Gypenoside L also can activate p38 and ERK MAPK pathways and NF-κB pathway to induce senescence. Gypenoside L exhibits anti-tumor and anti-inflammatory activities .

HY-N3924

Ganoderiol F

Others Others

Ganoderiol F, a tetracyclic triterpene, is isolated from Ganoderma amboinense and found to induce senescence of cancer cell lines .
HY-155771

1-DCP

Others Others

1-DCP is a potent ethylene antagonist. 1-DCP can inhibit the role of ethylene in fruit ripening and senescence .

Ganoderiol F	Others	Others
Ganoderiol F, a tetracyclic triterpene, is isolated from Ganoderma amboinense and found to induce senescence of cancer cell lines .

1-DCP	Others	Others
1-DCP is a potent ethylene antagonist. 1-DCP can inhibit the role of ethylene in fruit ripening and senescence .

HY-U00177

GDP366 1 Publications Verification	Survivin	Cancer
GDP366, a dual inhibitor of survivin and Op18, induces cell growth inhibition, cellular senescence and mitotic catastrophe in human cancer cells.

HY-N1931

Epifriedelanol
Epifriedelanol is a triterpenoid isolated from the root bark of Ulmus davidiana, with antitumor activity . Epifriedelanol inhibits cellular senescence in human primary cells .

HY-100023

LY3177833

CDK Cancer

LY3177833 (Example 4) is an orally active CDC7 and pMCM2 inhibitor with IC₅₀ values of 3.3 nM and 290 nM, respectively. LY3177833 is a senescence inducer .

LY3177833	CDK	Cancer
LY3177833 (Example 4) is an orally active CDC7 and pMCM2 inhibitor with IC₅₀ values of 3.3 nM and 290 nM, respectively. LY3177833 is a senescence inducer .

HY-100023A

LY3177833 monhydrate	CDK	Cancer
LY3177833 (Example 4) monhydrate is an orally active CDC7 and pMCM2 inhibitor with IC₅₀ values of 3.3 nM and 290 nM, respectively. LY3177833 monhydrate is a senescence inducer .

HY-N10083

Selaginellin	Reactive Oxygen Species Sirtuin	Cancer
Selaginellin is an inhibitor of Reactive Oxygen Species and an activator of SIRT1. Selaginellin protects endothelial cells against homocysteine-induced senescence by inhibitng reactive oxygen species and upregulating SIRT1 gene expression .

HY-126386

Pectinase, aspergillus niger EC 3.2.1.15	Others	Others
Pectinase (EC 3.2.1.15) is a mixed enzymes that hydrolyze pectic substances, it mostly presents in microorganisms and higher plants. Pectinase is involved in the metabolism of the cell wall as well as in the growth of the cell, senescence, ripening of fruits, pathogenesis and abscission process .

HY-101266

Milademetan 2 Publications Verification DS-3032
Milademetan (DS-3032) is a specific and orally active MDM2 inhibitor for the research of acute myeloid leukemia (AML) or solid tumors. Milademetan (DS-3032) induces G1 cell cycle arrest, senescence and apoptosis .

HY-101266B

Milademetan tosylate hydrate 2 Publications Verification DS-3032b; DS-3032 tosylate hydrate	MDM-2/p53 E1/E2/E3 Enzyme Apoptosis	Cancer
Milademetan (DS-3032) tosylate hydrate is a specific and orally active MDM2 inhibitor for the research of acute myeloid leukemia (AML) or solid tumors. Milademetan (DS-3032) tosylate hydrate induces G1 cell cycle arrest, senescence and apoptosis .

HY-P2096

Hexapeptide-11	Reactive Oxygen Species ATM/ATR MDM-2/p53	Infection
Hexapeptide-11 is a bioactive peptide with anti-aging effect. Hexapeptide-11 protects fibroblasts against oxidative stress-mediated premature cellular senescence by mediating a downregulation of cellular proteins, such as ataxia telangiectasia mutated (ATM) and p53 .

HY-17386A

Rosiglitazone hydrochloride Maximum Cited Publications 84 Publications Verification BRL 49653 hydrochloride
Rosiglitazone (BRL 49653) hydrochloride is an orally active selective PPARγ agonist (EC₅₀: 60 nM, K_d: 40 nM). Rosiglitazone hydrochloride is a TRPC5 activator (EC₅₀: 30 μM) and TRPM3 inhibitor. Rosiglitazone hydrochloride can be used in the research of obesity and diabetes, senescence, ovarian cancer .

HY-100355

C18-Ceramide	Endogenous Metabolite	Neurological Disease Cancer
C18-Ceramide can promote exocytosis of glutamate from damaged neurons. C18-Ceramide promotes cell death in glioma cells. Ceramides is involved in diverse cellular functions, such as differentiation, cell cycle progression, cell-cell adhesion, senescence, and apoptosis .

HY-13737

R1530 1 Publications Verification	VEGFR FGFR Apoptosis	Cancer
R1530 is a highly potent, orally active, dual-acting mitosis/angiogenesis inhibitor, with anti-tumor and anti-angiogenic activities. R1530 is a multikinase inhibitor which binds to 31 kinases with K_d values of <500 nM. R1530 inhibits VGFR2 and FGFR1 with IC₅₀ of 10 nM and 28 nM, respectively. R1530 triggers apoptosis (mitotic catastrophe) or senescence .

HY-101761

TM5441 5+ Cited Publications	PAI-1 Apoptosis	Cancer
TM5441 is an orally bioavailable inhibitor of plasminogen activator inhibitor-1 (PAI-1), has IC₅₀ values between 13.9 and 51.1 μM and induces intrinsic apoptosis in several human cancer cell lines. TM5441 attenuates Nω-nitro-l-arginine methyl ester-induced cardiac hypertension and vascular senescence .

HY-15523

Braco-19 3 Publications Verification	CMV DNA/RNA Synthesis	Cancer
Braco-19 is a potent telomerase/telomere inhibitor, preventing the capping and catalytic action of telomerase. Braco-19 acts as G-quadruplex (GQ) binding ligand, stabilizing G-quadruplexes formation at the 3V telomeric DNA overhang and produce rapid senescence or selective cell death. Braco-19 is also a HAdV virus replication inhibitor .

HY-15523A

Braco-19 trihydrochloride 3 Publications Verification	DNA/RNA Synthesis CMV	Infection Cancer
Braco-19 trihydrochloride is a potent telomerase/telomere inhibitor, preventing the capping and catalytic action of telomerase. Braco-19 acts as G-quadruplex (GQ) binding ligand, stabilizing G-quadruplexes formation at the 3V telomeric DNA overhang and produce rapid senescence or selective cell death. Braco-19 is also a HAdV virus replication inhibitor .

HY-N12386

SIRT1 activator 1	Sirtuin	Cancer
SIRT1 activator 1(compound 3) is a derivative of marine compound xyloallenoide A isolated from the mangrove fungus Xylaria sp.SIRT1 activator 1 shows angiogenic activities in zebrafish. SIRT1 activator 1 protects hEPC against AngII-induced senescence by increasing SIRT1 expression levels and balancing the AMPK/Akt signaling pathway .

HY-119698

BAP9THP SD 8339; N-Benzyl-9-(tetrahydro-2h-pyran-2-yl)adenine	Others	Others
BAP9THP is a synthetic cytokinin derivative and a growth regulator. BAP9THP promotes chlorophyll retention (and senescence delay) in plant tissues exceptionally strongly, and growth of tobacco callus almost as strongly as 6-Benzylaminopurine (BAP). BAP9THP induces adventitious shoot formation ignificantly more strongly than N6-isopentenyladenine or Kinetin .

HY-101761A

TM5441 sodium	PAI-1 Apoptosis
TM5441 is an orally bioavailable inhibitor of plasminogen activator inhibitor-1 (PAI-1), has IC₅₀ values between 13.9 and 51.1 μM. TM5441 induces intrinsic apoptosis in several human cancer cell lines. TM5441 attenuates Nω-nitro-l-arginine methyl ester-induced cardiac hypertension and vascular senescence .

HY-100237

SZL P1-41 5+ Cited Publications	E1/E2/E3 Enzyme Apoptosis	Cancer
SZL P1-41 is a specific Skp2 inhibitor, binds to the F-box domain of Skp2 to prevent Skp1 association and Skp2 SCF complex formation. SZL P1-41, like Skp2 deficiency, augments p27-mediated apoptosis/senescence, while it impairs Akt-driven glycolysis. Anti-tumor activities .

HY-P0096

Decapeptide-12	Tyrosinase Sirtuin	Inflammation/Immunology Endocrinology
Decapeptide-12, a small oligopeptide, is a tyrosinase inhibitor that interacts with C-terminal residue of tyrosinase (K_d: 61.1 μM). Decapeptide-12 is a competitive inhibitor of mushroom tyrosinase (IC₅₀: 40 µM). Decapeptide-12 also increases transcription of SIRT. Decapeptide-12 reduces melanin content in melanocytes. Decapeptide-12 is used for the research of melanogenesis, senescence, inflammation .

HY-120912

Gingerenone A	Keap1-Nrf2 Glutathione Peroxidase	Inflammation/Immunology
Gingerenone A is a Nrf2-Gpx4 activator with anti-breast-cancer properties. Gingerenone A results a delayed G2/M in cancer cells, following oxidative stress and senescence responses. Gingerenone A also alleviates ferroptosis in secondary liver injury (SLI) in dextran sodium sulfate (DSS)-induced colitis mice. Gingerenone A can be isolated from Zingiber officinale .

HY-N2025

Oroxin A	PPAR Glucosidase	Metabolic Disease
Oroxin A is the major component of an ethanol-water Oroxylum indicum (L.) Kurz (Bignoniaceae) seed extract (OISE). Oroxin A acts as a partial PPARγ agonist that can activate PPARγ transcriptional activation. Oroxin A activates PPARγ by docking into the PPARγ protein ligand-binding domain. Oroxin A also exhibits an inhibitory activity against α-glucosidase and an antioxidant capacity . Oroxin A exerts anti-breast cancer effects by inducing ER stress-mediated senescence .

HY-135775

BMVC 1 Publications Verification	G-quadruplex Telomerase DNA/RNA Synthesis	Cancer
BMVC is a potent G-quadruplex (G4) stabilizer and a selective telomerase inhibitor with an IC₅₀ of ~0.2 μM. BMVC inhibits Taq DNA polymerase with an IC₅₀ of ~2.5 μM. BMVC increases the melting temperature of G4 structure of telomere and accelerates telomere length shortening. Anticancer activities .

HY-16705

BRD4770 2 Publications Verification	Histone Methyltransferase	Cancer
BRD4770 is a histone methyltransferase G9a inhibitor. BRD4770 reduces di- and trimethylation of lysine 9 on histone H3 (H3K9) with an EC₅₀ of 5 µM, and has less or little effect toward H3K27me3, H3K36me3, H3K4me3, and H3K79me3. BRD4770 can activate the ataxia telangiectasia mutated (ATM) pathway and induce cell senescence .

HY-158106

AZD8421	CDK	Cancer
AZD8421 is a selective CDK2 inhibitor (IC₅₀: 9 nM) with selectivity for CDK1, CDK4 and CDK6. AZD8421 inhibits cancer cell proliferation by inhibiting pRB phosphorylation, inducing cell cycle arrest and senescence. AZD8421 demonstrated promising single efficacy and synergy with CDK4/6 inhibitors such as Palbociclib (HY-50767) in in vivo breast and ovarian models. AZD8421 also has potent single-agent inhibitory activity against drug-resistant breast cancer cells.

HY-W025074

BML-278	Sirtuin Histone Methyltransferase	Cancer
BML-278 is a SIRT1 activator (EC₁₅₀: 1 μM). BML-278 increases H3K9 methylation and inhibits H3K9 acetylation in both the paternal and maternal pronucleus. BML-278 improves early embryonic development. BML-278 arrests the cell cycle at the G1/S phase, and reduces senescence in primary human mesenchymal cells. BML-278 reduces tubulin acetylation in U937 cells. BML-278 also increases mitochondrial density in murine C2C12 myoblasts .

Cat. No.	Product Name

HY-L039

Reprogramming Compound Library	2038 compounds
Techniques for reprogramming somatic cells create new opportunities for drug screening, disease modeling, artificial organ development, and cell therapy. The development of reprogramming techniques has grown exponentially since Yamanaka reprogrammed somatic cells to become induced pluripotent stem cells (iPSCs) using four transcription factors, OCT4, SOX2, KLF4, and c-MYC in 2006. Despite the development of efficient reprogramming methods, most methods are inappropriate for clinical applications because they carry the risk of integrating exogenous genetic factors or use oncogenes. Alternative approaches, such as those based on miRNA, non-viral genes, non-integrative vectors, and small molecules, have been studied as possible solutions to the problems. Among these alternatives, small molecules are attractive options for clinical applications. Reprogramming using small molecules is inexpensive and easy to control in a concentration- and time-dependent manner. It offers a high level of cell permeability, ease of synthesis and standardization, and it is appropriate for mass-producing cells. MCE Reprogramming Compound Library contains a unique collection of 2038 compounds that act on reprogramming signaling pathways. These compounds are potential stimulators for reprogramming. This library is a useful tool for researching reprogramming and regenerative medicine.

Reprogramming Compound Library

2038 compounds

Techniques for reprogramming somatic cells create new opportunities for drug screening, disease modeling, artificial organ development, and cell therapy. The development of reprogramming techniques has grown exponentially since Yamanaka reprogrammed somatic cells to become induced pluripotent stem cells (iPSCs) using four transcription factors, OCT4, SOX2, KLF4, and c-MYC in 2006. Despite the development of efficient reprogramming methods, most methods are inappropriate for clinical applications because they carry the risk of integrating exogenous genetic factors or use oncogenes. Alternative approaches, such as those based on miRNA, non-viral genes, non-integrative vectors, and small molecules, have been studied as possible solutions to the problems. Among these alternatives, small molecules are attractive options for clinical applications. Reprogramming using small molecules is inexpensive and easy to control in a concentration- and time-dependent manner. It offers a high level of cell permeability, ease of synthesis and standardization, and it is appropriate for mass-producing cells.

MCE Reprogramming Compound Library contains a unique collection of 2038 compounds that act on reprogramming signaling pathways. These compounds are potential stimulators for reprogramming. This library is a useful tool for researching reprogramming and regenerative medicine.

HY-L134

Anti-Aging Natural Product Library	193 compounds
Aging is an unavoidable process, leading to cell senescence due to physiochemical changes in an organism. Aging cells cease to divide and drive the progression of illness through various pathways, resulting in the death of an organism ultimately. Anti-aging activities are primarily involved in the therapies of age-related disorders such as Parkinson's Disease (PD), Alzheimer's Disease (AD), cardiovascular diseases, cancer, and chronic obstructive pulmonary diseases. Natural products are known as effective molecules in anti-aging treatments, which delay the aging process through influencing several pathways and thus ensure an extended lifespan. MCE offers a unique collection of 193 natural products with validated anti-aging activity. MCE anti-aging natural product library is a useful tool for the study of aging-related diseases drugs and pharmacology.

Anti-Aging Natural Product Library

193 compounds

Aging is an unavoidable process, leading to cell senescence due to physiochemical changes in an organism. Aging cells cease to divide and drive the progression of illness through various pathways, resulting in the death of an organism ultimately. Anti-aging activities are primarily involved in the therapies of age-related disorders such as Parkinson's Disease (PD), Alzheimer's Disease (AD), cardiovascular diseases, cancer, and chronic obstructive pulmonary diseases.

Natural products are known as effective molecules in anti-aging treatments, which delay the aging process through influencing several pathways and thus ensure an extended lifespan. MCE offers a unique collection of 193 natural products with validated anti-aging activity. MCE anti-aging natural product library is a useful tool for the study of aging-related diseases drugs and pharmacology.

HY-L034

Anti-Aging Compound Library	4329 compounds
Aging is a complex biological process characterized by functional decline of tissues and organs, structural degeneration, and reduced adaptability and resistance, all of which contribute to an increase in morbidity and mortality caused by multiple chronic diseases, such as Alzheimer's disease, cancer, and diabetes. Many theories, which fall into two main categories: programmed and error theories, have been proposed to explain the process of aging, but neither of them appears to be fully satisfactory. The programmed theories imply that aging relies on specific gene regulation, and the error theories emphasize the internal and environmental damages accumulated to living organisms. The damage theories proposed the nine hallmarks that were generally considered to contribute to the aging process: genomic instability, telomere attrition, epigenetic alterations, loss of proteostasis, deregulated nutrient-sensing, mitochondrial dysfunction, cellular senescence, stem cell exhaustion, and altered intercellular communication. MCE Anti-Aging Compound Library contains 4329 compounds, mainly targeting Sirtuin, mTOR, IGF-1R, AMPK, p53, Telomerase, Mitophagy, Mitochondrial Metabolism, COX, Cytochrome P450, Oxidase, etc. This library is a useful tool for anti-aging research.

Anti-Aging Compound Library

4329 compounds

Aging is a complex biological process characterized by functional decline of tissues and organs, structural degeneration, and reduced adaptability and resistance, all of which contribute to an increase in morbidity and mortality caused by multiple chronic diseases, such as Alzheimer's disease, cancer, and diabetes. Many theories, which fall into two main categories: programmed and error theories, have been proposed to explain the process of aging, but neither of them appears to be fully satisfactory. The programmed theories imply that aging relies on specific gene regulation, and the error theories emphasize the internal and environmental damages accumulated to living organisms. The damage theories proposed the nine hallmarks that were generally considered to contribute to the aging process: genomic instability, telomere attrition, epigenetic alterations, loss of proteostasis, deregulated nutrient-sensing, mitochondrial dysfunction, cellular senescence, stem cell exhaustion, and altered intercellular communication.

MCE Anti-Aging Compound Library contains 4329 compounds, mainly targeting Sirtuin, mTOR, IGF-1R, AMPK, p53, Telomerase, Mitophagy, Mitochondrial Metabolism, COX, Cytochrome P450, Oxidase, etc. This library is a useful tool for anti-aging research.

Hexapeptide-11	Reactive Oxygen Species ATM/ATR MDM-2/p53	Infection
Hexapeptide-11 is a bioactive peptide with anti-aging effect. Hexapeptide-11 protects fibroblasts against oxidative stress-mediated premature cellular senescence by mediating a downregulation of cellular proteins, such as ataxia telangiectasia mutated (ATM) and p53 .

Decapeptide-12	Tyrosinase Sirtuin	Inflammation/Immunology Endocrinology
Decapeptide-12, a small oligopeptide, is a tyrosinase inhibitor that interacts with C-terminal residue of tyrosinase (K_d: 61.1 μM). Decapeptide-12 is a competitive inhibitor of mushroom tyrosinase (IC₅₀: 40 µM). Decapeptide-12 also increases transcription of SIRT. Decapeptide-12 reduces melanin content in melanocytes. Decapeptide-12 is used for the research of melanogenesis, senescence, inflammation .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks